

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Taik Koo YUN et al. Conf.:
Appl. No.: NEW Group: 1654
Filed: July 8, 2003 Examiner: SUSAN D. COE
For: CANCER PREVENTIVE COMPOSITION COMPRISING
GINSEOSIDE GLYCOSIDES OF RED GINSENG

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 8, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
10/067,760

U.S. Filing Date(s)
February 8, 2002

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #53868
Joseph A. Kolasch, #22,463

h
JAK/TBS/jmb
0662-0189P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)
☒ References
☐ Foreign Search Report
☐ Other:

(Rev. 04/29/03)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTY DOCKET NO. 0662-0189P	APPLICATION NO. NEW
	APPLICANT Taik Koo YUN et al.	
	FILING DATE July 8, 2003	GROUP 1651

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 5,776,460		1998-07-07	KIM et al.			
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	WO	97/18824	A1	1997-05-29	PCT				

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	Charles H. HENNEKENS, M.D. et al., The New England Journal of Medicine, Vol. 334, No. 18, (May 2, 1996), pp.1145-1155.
	Ming YOU, M.D. et al., Cancer Chemoprevention, Vol. 12, No. 5, (October 1996), pp.1037-1053.
	Christopher R. HERZOG et al., Journal of Cellular Biochemistry Supplements, Vol. 28/29, (1997), pp.49-63.
	Young-Joon SURH et al., J. Korean Med. Sci., Vol. 16, (2001), pp.S38-S-41.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	